Table 2 Promising mimetics and inhibitor therapeutic agents for cancer

ABT-737

BH3-M

Structure-based design,

BAK peptide

Bcl-2, Bcl-xL

–

Abbott Labs. (IL, USA)

[58]

Navitoclax

BH3-M

ABT-737

Bcl-2, Bcl-xL, Mcl1

Mcl1 (weak)

Abbott Labs. (IL, USA)

[59]

Gossypol

(AT-101)

BH3-M

Structure-based design,

BIM peptide

Bcl-2, Bcl-xL, Mcl1

–

University of Michigan (MI, US)

[60]

Obatoclax

BH3-M

In silico docking studies

Bcl-2, Mcl1

Bcl-xL

University of Montreal (CAN)

[61]

Venetoclax

BH3-M

Navitoclax

Bcl-2

Bcl-xL (weak)

AbbieVie (IL, USA)

[62]

Compound 3

Smac-M

Smac (AVPI/AVPF

peptide sequence)

xIAP, cIAP1/2

NF-κB activation

University of Texas (TX, USA)

[63]

[64]

APG1387

Smac-M

Smac (AVPI peptide sequence)

xIAP, cIAP1/2

–

University of Michigan (MI, USA)

[65]

AT-406

Smac-M

Structure-based design

xIAP, cIAP1/2

–

University of Michigan (MI, USA)

[66]

Compound A

Smac-M

Small molecule screen

xIAP, cIAP1/2

–

University of Texas (TX, USA)

[63]

LC161

Smac-M

Structure-based design

xIAP, cIAP1/2

–

Dana-Farber CI (MA, US)

[67]

SM-164

Smac-M

Structure-based design

xIAP

–

University of Michigan (MI, USA)

[68]

Birinapant

Smac-M

Smac (AVPI peptide sequence)

cIAP1

xIAP (weak)

Duke University (NC, USA)

[69]

A1210477

Mcl1-I

High throughput screen

Mcl1

–

AbbieVie (IL, USA)

Genetech (CA, US)

[70]

[71]

AMG-176

Mcl1-I

Structure-based design,

High throughput screen

Mcl1

Bcl-2, Bcl-xL (minimal)

Amgen (CA, USA)

[72]

AZD-5991

Mcl1-I

Structure-based design

Mcl1

–

AstraZeneca (MA, US)

[73]

S63845

Mcl1-I

In-silico modelling

Mcl1

–

Institut de Recherches Servier Oncology (FRA)

[74]

MIM1

Mcl1-I

Small molecule screen

Mcl1

–

Dana-Farber CI (MA, USA)

[75]

VU661013

Mcl1-I

Structure-based design

Mcl1

BIM-Mcl1 destabilization

Vanderbilt University (TN, USA)

[76]

[77]

GDC-0941

Mcl1-I

In-silico modelling

PI3Kα/δ, Mcl1

–

Piramed Pharma (UK)

[78]